<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182650</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000438797</org_study_id>
    <secondary_id>R21CA105824</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-IRB-01160</secondary_id>
    <nct_id>NCT00182650</nct_id>
  </id_info>
  <brief_title>Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated&#xD;
      in the laboratory to stimulate the immune system in different ways and stop cancer cells from&#xD;
      growing. Rituximab and fludarabine may also prevent the body from making an immune response&#xD;
      against the laboratory-treated white blood cells that are put back into the body.&#xD;
      Interleukin-2 may help the laboratory-treated white blood cells stay in the body longer.&#xD;
      Giving cellular adoptive immunotherapy together with rituximab, fludarabine, and&#xD;
      interleukin-2 may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy&#xD;
      in treating patients with relapsed or refractory follicular non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of cellular adoptive immunotherapy using autologous&#xD;
           cytotoxic T lymphocytes genetically modified to express a CD19-specific chimeric&#xD;
           immunoreceptor gene and HyTK selection/suicide gene in patients with relapsed or&#xD;
           refractory follicular non-Hodgkin's lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the in vivo persistence of adoptively transferred cytolytic T cells in&#xD;
           patients treated with lymphodepleting therapy comprising rituximab and fludarabine.&#xD;
&#xD;
        -  Assess the development of host immune responses against the CD19-specific chimeric&#xD;
           immunoreceptor gene and/or HyTK selection/suicide gene.&#xD;
&#xD;
        -  Determine the safety of low-dose interleukin-2 in supporting in vivo persistence of&#xD;
           adoptively transferred cytotoxic T cells.&#xD;
&#xD;
        -  Determine the anti-tumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, pilot study.&#xD;
&#xD;
        -  Leukapheresis: Patients undergo leukapheresis for collection of peripheral blood&#xD;
           mononuclear cells (PBMCs). CD3-positive cytotoxic T lymphocytes (CTLs) are isolated and&#xD;
           genetically modified to express a CD19-specific chimeric immunoreceptor and the HyTK&#xD;
           fusion protein, and are then expanded in vitro.&#xD;
&#xD;
        -  Lymphodepleting therapy: Patients receive rituximab and fludarabine prior to T-cell&#xD;
           infusions.&#xD;
&#xD;
        -  Cellular adoptive immunotherapy and interleukin-2 (IL-2): Patients receive a total of 5&#xD;
           infusions of genetically modified autologous T cells. Patients may receive low-dose IL-2&#xD;
           subcutaneously after infusions 3, 4, and 5.&#xD;
&#xD;
        -  Additional IL-2 therapy: After the completion of the last T-cell infusion, patients with&#xD;
           evidence of adoptively transferred T cells may receive additional IL-2.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for approximately 65&#xD;
      days and then annually for at least 15 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 5 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed follicular non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  High-risk disease, as defined by any of the following:&#xD;
&#xD;
                    -  Relapsed within 6 months after the last treatment&#xD;
&#xD;
                    -  Failed to achieve a complete response during the last treatment&#xD;
&#xD;
                    -  Relapsed after prior autologous hematopoietic stem cell transplantation&#xD;
                       (HSCT)&#xD;
&#xD;
          -  No current transformation of lymphoma (e.g., elements of intermediate- or high-grade&#xD;
             lymphoma by biopsy)&#xD;
&#xD;
          -  No active CNS disease by lumbar puncture or radiology scan NOTE: A new classification&#xD;
             scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
             terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 16 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)* (unless due to Gilbert's disease)&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN* NOTE: *Unless due to NHL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN* OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 80 mL/min* NOTE: *Unless due to NHL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Epstein-Barr virus positive&#xD;
&#xD;
          -  No history of allergy or intolerance to ganciclovir&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No history of another malignancy except basal cell skin cancer or carcinoma in situ&#xD;
&#xD;
          -  No other uncontrolled or severe illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior allogeneic HSCT&#xD;
&#xD;
          -  No other immunotherapy during and for approximately 65 days after the last T-cell&#xD;
             infusion, unless approved by the Principal Investigator (PI)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No other chemotherapy during and for approximately 65 days after the last T-cell&#xD;
             infusion, unless approved by the PI&#xD;
&#xD;
               -  Patients may receive chemotherapy after leukapheresis while waiting for&#xD;
                  CD19-specific T cells to be manufactured&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No systemic corticosteroids during and for approximately 65 days after the last T-cell&#xD;
             infusion, unless approved by the PI&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in another investigational study&#xD;
&#xD;
          -  No immunosuppression agents or other investigational agents during and for&#xD;
             approximately 65 days after the last T-cell infusion, unless approved by the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2009</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

